Application of Cytokines and Synthetic Peptides for Increase in Immunogenicity of Melioidosis Antigens
https://doi.org/10.21055/0370-1069-2014-3-83-85
Abstract
B. pseudomallei 100 resistance (61.5 % of survived animals). It was concluded that it is a good practice to include bestim in the schedule of complex immunization against melioidosis.
About the Authors
O. B. Dem’Yanova
Volgograd Research Anti-Plague Institute
Russian Federation
Russian Federation
S. I. Zhukova
Volgograd Research Anti-Plague Institute
Russian Federation
Russian Federation
A. A. Zankovich
Volgograd Research Anti-Plague Institute
Russian Federation
Russian Federation
N. P. Khrapova
Volgograd Research Anti-Plague Institute
Russian Federation
Russian Federation
K. A. Rotov
Volgograd Research Anti-Plague Institute
Russian Federation
Russian Federation
N. N. Sintyurina
Volgograd Research Anti-Plague Institute
Russian Federation
Russian Federation
E. A. Snatenkov
Volgograd Research Anti-Plague Institute
Russian Federation
Russian Federation
References
1. Avrorova I.V., Zhukova S.I., Korsakova I.I., Khrapova N.P., Napalkova G.N. [Burkholderia pseudomallei surface biopolymers and their protective activity in experimental melioidosis]. Infek. Patol. 2010; 17(3):85–7.
2. Glants S. [Medical-Biological Statistics]. M.: Praktika; 1998. 459 p.
3. Zhukova S.I., Avrorova I.V., Proshina O.B., Rotov K.A., Khrapova N.P., Snatenkov E.A., Lomova L.V. [Method of immunoprophylaxis of experimental melioidosis using Burkholderia pseudomallei entrapped antigens]. RF Patent 2373955. 27.11.2009. Bull. 33.
4. Karaulov A.V. [Clinical-immunological efficacy of immunofan application in case of opportunistic infections]. Lechashchii Vrach. 2000; 4:52–5.
5. Karaulov A.V., Sokurenko S.I. [Immunofan: short term and remote results of curative treatment among the patients with chronic bronchitis]. Medical Market. 2000; 34:21–4.
6. Kukarkin N.Yu., Dolgushin I.I., Bordunovsky V.N. [Bestim in the treatment of patients with chronic pyelonephritis]. In: [Immunity and Diseases: Translation of Theory into Practice]. M.; 2005. P. 90–1.
7. Lapach S.N., Chubenko A.V., Babich P.N. [Statistical Methods in Medical Biological Investigations using Excel Software]. Kiev: Morion; 2001. 408 p.
8. Lyubimov G.Yu., Zenkov N.G., Vol’sky N.N. [Chemoluminescence of peritoneal macrophages if exposed to macrophage-activation factor]. Immunologiya. 1992; 1:40–3.
9. Popova A.E. [Methodoligical recommendations for identification of edemagenic effect on white mice]. Volgograd; 1980. 18 p.
10. Sentsova T.B. [Modern immune-modulators]. Otorinolaringologiya. 2004; 3(5):16–8.
11. Simbirtsev A.S., Sakharova I.Ya., Vasil’eva G.Yu., Balasanyants G.S., Bokovanov V.E. [Experience in usage of bestim in the complex treatment of infiltrative and destructive forms of pulmonary tuberculosis]. Ros. Semeinyi Vrach. 2003; 3:17–9.
12. Barnes J.L., Warner J., Melrose W. Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. Clin. Immunol. 2004; 113(1):22–8.
13. Ketheesan N., Barnes J.L., Ulett G.C. Demonstration of a cell-mediated immune response in melioidosis. J. Infect. Dis. 2002; 186(2):286–9.
Review
For citations:
Dem’Yanova O.B., Zhukova S.I., Zankovich A.A., Khrapova N.P., Rotov K.A., Sintyurina N.N., Snatenkov E.A. Application of Cytokines and Synthetic Peptides for Increase in Immunogenicity of Melioidosis Antigens. Problems of Particularly Dangerous Infections. 2014;(3):83-85. (In Russ.) https://doi.org/10.21055/0370-1069-2014-3-83-85
Views:
722
Email this article 